Abzena Ltd. is following in the footsteps of other revenue-generating U.K. biopharma service companies by seeking a listing on the LSE's AIM market. CEO John Burt told BioCentury the listing will provide the company enough cash to grow both organically and through bolt-on acquisitions.

Abzena was formed last year through the merger of two biologics services companies: PolyTherics Ltd. and Antitope Ltd. Burt said the pair provide complementary services: PolyTherics offers its